Rapport Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RAPP | PRAX | ANRO | GPCR | MPLT | ACAD | |
|---|---|---|---|---|---|---|
| Market cap | 1.50B | 7.95B | 914.34M | 1.45B | 372.91M | 3.70B |
| P/E (TTM) | — | — | — | — | — | 9.6 |
| Forward P/E | -5.1 | -30.0 | -7.3 | -9.6 | -2.0 | 23.3 |
| Price/book | 3.2 | 5.9 | 3.7 | 1.1 | 0.9 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −2.79% | +70.38% | +109.34% | −39.17% | −58.43% | −7.88% |
| Today | +1.93% | +1.53% | +2.64% | +0.05% | −1.47% | +4.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RAPP news ›Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport” or the "Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision…
Contrasting Rapport Therapeutics (NASDAQ:RAPP) & Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)
Posted by Kim Johansen on Nov 3rd, 2026 Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) and Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) are both healthcare companies, but which is the better business?…
Rapport Therapeutics prices $200M stock offering
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations uniQure Announces…
Rapport Therapeutics offers $150M in convertible notes
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations Aehr Test Systems…
Rapport Therapeutics: Sofinnova buys 952K shares
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations uniQure Announces…
Rapport Therapeutics, Inc. Stock 12‑Month Price Target Cut to $68.29, Implies 173% Upside
TradingView Rapport Therapeutics, Inc. Stock 12‑Month Price Target Cut to $68.29, Implies 173% Upside - According to estimates from 14 analysts, Rapport Therapeutics, Inc. stock's average price target has fall
Rapport Therapeutics (NASDAQ: RAPP) director buys $20.36 million of stock via funds
Posted by Danessa Lincoln on Oct 31st, 2026 Director James Healy bought 969,480 shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) at $21.00 each on Oct. 28, for $20.36 million. The shares were bought through four fund vehicles over which…
Rapport Therapeutics (NASDAQ:RAPP) Stock Jumps 7.8% – Here’s Why
Posted by Danessa Lincoln on Oct 31st, 2026 Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) shares shot up 7.8% on Thursday. The company traded as high as $23.65 and last traded at $24.26. Approximately 223,703 shares changed…
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks…
Rapport Therapeutics Prices $380 Million Stock And Convertible Notes Offerings; Stock Down
Rapport Therapeutics, Inc. (RAPP) announced the pricing of separate public offerings of common stock and convertible senior notes, along with a concurrent private placement, with the transactions expected to raise approximately $380…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com7
- stocktitan.net6
- themarketsdaily.com4
- seekingalpha.com2
- tradingview.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 26 articles, not a forecast.